Lv574
1170 积分 2025-08-21 加入
Preoperative Co-Mutation of BRAF V600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma
6天前
已完结
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
1个月前
已完结
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
1个月前
已完结
Medullary Thyroid Cancer Risk and Mortality in Carriers of Incidentally Identified MEN2A RET Variants
1个月前
已完结
Multifocal papillary thyroid carcinoma with RET p.V804M, EML4-ALK fusion, and BRAF V600E positivity
1个月前
已完结
Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma
3个月前
已完结
甲状腺未分化癌诊疗专家共识(2023版)
3个月前
已关闭
Cytomorphologic and Histologic Correlation on TERT Promotor Mutations in Thyroid Tumors: One Institutional Experience
3个月前
已关闭
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
3个月前
已完结
皖公网安备34019202002308
